Axsome Therapeutics
Open enrollment with a later-stage pipeline tilt
According to ClinicalTrials.gov-derived indexes, Axsome Therapeutics sits in the top decile of US sponsors by registered trial count (#568 of 15,742 sponsors by registered trial count).
Axsome Therapeutics: 28 sponsored US clinical trials, 6 recruiting.
Axsome Therapeutics sponsors 28 registered US clinical trials on ClinicalTrials.gov, 6 of them currently recruiting, and 20 completed. 21 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Major Depressive Disorder, with 3 trials.
Top-decile sponsor footprint
Axsome Therapeutics ranks in the top decile of sponsors by registered trial count (#568 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
20 of 22 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (90.9%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
28 total, page 1 of 1
Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol
NCT07484217
Fibromyalgia Response With Esreboxetine Evaluated Using a Randomized Withdrawal Research Design
NCT07398417
Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN)
NCT06568367
Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol
NCT06413433
A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms
NCT06223880
SUNOSI® (Solriamfetol) Pregnancy Registry
NCT06413420
An Open-Label Study to Assess the Long-term Safety of AXS-05 in Subjects With Dementia of the Alzheimer's Type, ADVANCE-2 and ACCORD-2 Extension Study
NCT06736509
Progressing TAAR-1, Dopamine, and Norepinephrine in Depression Using Solriamfetol
NCT06360419
A Study to Assess the Efficacy and Safety of Solriamfetol in Subjects With ADHD (FOCUS)
NCT05972044
A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation
NCT05557409
Open-Label Study of AXS-07 for the Acute Treatment of Migraine in Adults With a Prior Inadequate Response to an Oral CGRP Inhibitor (EMERGE)
NCT05550207
A Study to Assess the Long-term Efficacy and Safety of AXS-12 (Reboxetine) in Subjects With Narcolepsy (ENCORE)
NCT05113745
A Study to Assess the Efficacy and Safety of AXS-12 (Reboxetine) in Patients With Narcolepsy
NCT05059223
Evaluate Sunosi® PK in Breast Milk and Plasma of Healthy Postpartum Women Following Single Dose Oral Administration
NCT05008341
A Study to Assess the Long-term Safety and Efficacy of AXS-05 in Subjects With Alzheimer's Disease Agitation
NCT04947553
Solriamfetol's Effect on Cognitive Health in Apnea Participants During a Randomized Placebo-controlled Study
NCT04789174
Assessing Clinical Outcomes in Alzheimer's Disease Agitation
NCT04797715
Open-Label Safety Study of AXS-05 in Subjects With TRD (EVOLVE)
NCT04634669
Mechanistic Evaluation of Response in TRD (MERIT)
NCT04608396
Initiating Early Control of Migraine Pain and Associated Symptoms
NCT04163185
Open-Label Safety Study of AXS-05 in Subjects With Depression
NCT04039022
Multimechanistic Treatment Over Time of Migraine Symptoms (MOVEMENT)
NCT04068051
A Trial of AXS-05 in Patients With Major Depressive Disorder
NCT04019704
Clinical Outcomes in Narcolepsy and Cataplexy: An Evaluation of Reboxetine Treatment (CONCERT)
NCT03881852
Maximizing Outcomes in Treating Acute Migraine
NCT03896009
Assessing Symptomatic Clinical Episodes in Depression
NCT03595579
Addressing Dementia Via Agitation-Centered Evaluation
NCT03226522
A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Treatment Resistant Major Depressive Disorder
NCT02741791
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 5 |
| Phase 3 | 19 |
| Phase 4 | 2 |
Therapeutic Areas
Where Axsome Therapeutics enrollment is open (later-stage tilt)
6 recruiting of 28 indexed (21% open); 20 completed (71%).
Phase mix: 21 late (III/IV) vs 6 early (I/II) (later-stage heavy).
Top condition: Major Depressive Disorder (3 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Axsome Therapeutics: open-pipeline peers nationwide
Peers matched on 28 registered trials and 21% open enrollment, not the therapeutic-area sidebar.
Axsome Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 28 trials (± recruiting share)
- Benaroya Research Institute · 28 trials · 14% recruiting
- CAMC Health System · 28 trials · 11% recruiting
- CTI BioPharma · 28 trials · 0% recruiting
- Harvard Pilgrim Health Care · 28 trials · 4% recruiting
Sponsors near 21% open enrollment (± trial volume)
- GOG Foundation · 21% recruiting · 14 trials
- Kettering Health Network · 21% recruiting · 14 trials
- LifeBridge Health · 21% recruiting · 14 trials
- Olympus Corporation of the Americas · 21% recruiting · 14 trials
Related
What to do with this Axsome Therapeutics page
28 registered trials is a research-attention snapshot, not an endorsement of Axsome Therapeutics or any single study.
- 6 of Axsome Therapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Major Depressive Disorder is the condition Axsome Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Major Depressive Disorder trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Axsome Therapeutics pipeline card: 28 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.